AstraZeneca has delivered robust results for the first nine months of 2025, underscoring its position as a global biopharmaceutical leader with diversified strength across therapeutic areas and regions. 

 

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy, supported by strong demand in Oncology and Respiratory & Immunology (R&I). 

 

With double-digit profit expansion and a surge in clinical and regulatory milestones, AstraZeneca continues to balance near-term commercial success with long-term innovation-driven growth.

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: 'The strong underlying momentum across our business through the 

first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition."

 

'Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results

including high-impact readouts for baxdrostat in hypertension and Enhertu and Datroway in breast cancer.

 

"We are also delivering on our strategy to strengthen our operations in the United States to power our growth. This includes a historic 

agreement with the US government to lower the cost of medicines for American patients, and broadening our US manufacturing footprint having broken ground at our new $4.5bn Virginia manufacturing facility in October.”